A Transcriptomics Approach To Unveiling the Mechanisms of In Vitro Evolution towards Fluconazole Resistance of a Candida glabrata Clinical Isolate
Open Access
- 1 January 2019
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 63 (1)
Abstract
Candida glabrata is an emerging fungal pathogen. Its increased prevalence is associated with its ability to rapidly develop antifungal drug resistance, particularly to azoles. In order to unravel new molecular mechanisms behind azole resistance, a transcriptomics analysis of the evolution of a C. glabrata clinical isolate (isolate 044) from azole susceptibility to posaconazole resistance (21st day), clotrimazole resistance (31st day), and fluconazole and voriconazole resistance (45th day), induced by longstanding incubation with fluconazole, was carried out. All the evolved strains were found to accumulate lower concentrations of azole drugs than the parental strain, while the ergosterol concentration remained mostly constant. However, only the population displaying resistance to all azoles was found to have a gain-of-function mutation in the C. glabrataPDR1 gene, leading to the upregulation of genes encoding multidrug resistance transporters. Intermediate strains, exhibiting posaconazole/clotrimazole resistance and increased fluconazole/voriconazole MIC levels, were found to display alternative ways to resist azole drugs. Particularly, posaconazole/clotrimazole resistance after 31 days was correlated with increased expression of adhesin genes. This finding led us to identify the Epa3 adhesin as a new determinant of azole resistance. Besides being required for biofilm formation, Epa3 expression was found to decrease the intracellular accumulation of azole antifungal drugs. Altogether, this work provides a glimpse of the transcriptomics evolution of a C. glabrata population toward multiazole resistance, highlighting the multifactorial nature of the acquisition of azole resistance and pointing out a new player in azole resistance.Keywords
Funding Information
- Science Foundation Ireland (12/IA/1343)
- MEC | Fundação para a Ciência e a Tecnologia (PTDC/BBB-BIO/4004/2014, UID/BIO/04565/2013, PTDC/BII-BIO/28216/2017)
This publication has 52 references indexed in Scilit:
- Emerging and Emerged Pathogenic Candida Species: Beyond the Candida albicans ParadigmPLOS Pathogens, 2013
- Interactions between copy number and expression level of genes involved in fluconazole resistance in Candida glabrataFrontiers in Cellular and Infection Microbiology, 2013
- Facultative Sterol Uptake in an Ergosterol-Deficient Clinical Isolate of Candida glabrata Harboring a Missense Mutation in ERG11 and Exhibiting Cross-Resistance to Azoles and Amphotericin BAntimicrobial Agents and Chemotherapy, 2012
- Comparative Lipidomics in Clinical Isolates of Candida albicans Reveal Crosstalk between Mitochondria, Cell Wall Integrity and Azole ResistancePLOS ONE, 2012
- Requirement for Ergosterol in V-ATPase Function Underlies Antifungal Activity of Azole DrugsPLOS Pathogens, 2010
- Gain of Function Mutations in CgPDR1 of Candida glabrata Not Only Mediate Antifungal Resistance but Also Enhance VirulencePLOS Pathogens, 2009
- Development of a Highly Efficient Gene Targeting System Induced by Transient Repression of YKU80 Expression in Candida glabrataEukaryotic Cell, 2007
- The Yeast Gene Order Browser: Combining curated homology and syntenic context reveals gene fate in polyploid speciesGenome Research, 2005
- Drag&Drop cloning in yeastGene, 2005
- In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance programDiagnostic Microbiology and Infectious Disease, 2004